The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?
Donald S. Silverberg(Tel Aviv Sourasky Medical Center), Adrian Iaina(Tel Aviv Sourasky Medical Center), Dov Wexler
Cited by 92
Related Papers
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
|The Lancet|2000|1k
The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations
|Journal of the American College of Cardiology|2000|729
The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study
|Journal of the American College of Cardiology|2001|645
Randomised crossover trial of naltrexone in uraemic pruritus
|The Lancet|1996|298